SEARCH

SEARCH BY CITATION

References

  • 1
    Saag KG. Glucocorticoid-induced osteoporosis. Endocrinol Metab Clin North Am. 2003; 32:13557.
  • 2
    Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton LJ III, Tenenhouse A, Reeve J, Silman AJ, Pols HAP, Eisman JA, McCloskey EV, Mellstrom D. A meta-analysis of prior corticoid use and fracture risk. J Bone Miner Res. 2004; 19:8939.
  • 3
    Angeli A, Guglielmi G, Dovio A, Capelli G, de Feo D, Giannini S, Giorgino R, Moro L, Giustina A. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone. 2006; 39:2539.
  • 4
    Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007; 18:131928.
  • 5
    van Staa TP, Lann RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003; 48:32249.
  • 6
    Ito M, Ikeda K, Nishiguchi M, Shindo H, Uetani M, Hosoi T, Orimo H. Multi-detector row CT imaging of vertebral microstructure for evaluation of fracture risk. J Bone Miner Res. 2005; 20:182836.
  • 7
    Graeff C, Timm W, Nickelsen TN, Farrerons J, Marín F, Barker C. Glüer CC for the EUROFORS High Resolution Quantitative Computed Tomography Substudy Group. Monitoring teriparatide associated changes in vertebral microstructure by high-resolution computed tomography in vivo: Results from the EUROFORS study. J Bone Miner Res. 2007; 22:142633.
  • 8
    Krebs A, Graeff C, Frieling I, Kurz B, Timm W, Engelke K, Glüer CC. High resolution computed tomography of the vertebrae yields accurate information on trabecular distances if processed by 3D fuzzy segmentation approaches. Bone. 2009; 44:14552.
  • 9
    Kalpakcioglu BB, Engelke K, Genant HK. Advanced imaging assessment of bone fragility in glucocorticoid-induced osteoporosis. Bone. 2011; 48:122131.
  • 10
    Faulkner KG, Cann CE, Hasegawa BH. Effect of bone distribution on vertebral strength: assessment with patient-specific nonlinear finite element analysis. Radiology. 1991; 179:66974.
  • 11
    Glüer CC. Quantitative computed tomography in children and adults. In: Rosen CJ, Compston JE, Lian JB, editors. Primer on the metabolic bone diseases and disorders of mineral metabolism. 7th edition, American Society for Bone and Mineral Research; Washington, USA: p. 15862. 2008.
  • 12
    Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ. PaTH Study Investigators. One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med. 2005; 353:55565.
  • 13
    Keaveny TM, Donley DW, Hoffmann PF, Mitlak BH, Glass EV, San Martin JA. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res. 2007; 22:14957.
  • 14
    Graeff C, Chevalier Y, Charlebois M, Varga P, Pahr D, Nickelsen TN, Morlock MM, Glüer CC, Zysset PK. Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: results from the EUROFORS Study. J Bone Miner Res. 2009; 24:167280.
  • 15
    Finkelstein JS, Wyland JJ, Lee H, Neer RM. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2010; 95:183845.
  • 16
    Chevalier Y, Quek E, Borah B, Gross G, Stewart J, Lang T, Zysset P. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body. Bone. 2010; 46:418.
  • 17
    Rehman Q, Lang TF, Arnaud CD, Modin GW, Lane NE. Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporosis Int. 2003; 14:7781.
  • 18
    Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003; 349:121626.
  • 19
    Adler RA, Hochberg MC. Glucocorticoid-induced osteoporosis in men. J Endocrinol Invest. 2011; 34:4814.
  • 20
    Graeff C, Marin F, Petto H, Kayser O, Reisinger A, Peña J, Zysset P, Glüer CC. High resolution quantitative computed tomography-based assessment of trabecular microstructure and strength estimates by finite-element analysis of the spine, but not DXA, reflects vertebral fracture status in men with glucocorticoid-induced osteoporosis. Bone. 2013 Feb; 52(2):56877.
  • 21
    Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010; 25:146886.
  • 22
    Simmons CA, Hipp JA. Method-based differences in the automated analysis of the three-dimensional morphology of trabecular bone. J Bone Miner Res. 1997; 12:9427.
  • 23
    Chevalier Y, Charlebois M, Pahra D, Varga P, Heini P, Schneider E, Zysset P. A patient-specific finite element methodology to predict damage accumulation in vertebral bodies under axial compression, sagittal flexion and combined loads. Comput Methods Biomech Biomed Engin. 2008; 11:47787.
  • 24
    Chevalier Y, Zysset P. A patient-specific CT-based finite element methodology to calculate the 6D stiffness matrix of vertebral bodies. XXXIV Congress of the Société de Biomécanique, Toulon, France. Comput Methods Biomech Biomed Engin. 2009; 12(Suppl 1):779.
  • 25
    Dall'Ara E, Pahr D, Varga P, Kainberger F, Zysset P. QCT-based finite element models predict human vertebral strength in vitro significantly better than simulated DEXA. Osteoporos Int. 2012; 23:56372.
  • 26
    Genant HK, Grampp S, Gluer CC, Faulkner KG, Jergas M, Engelke K, Hagiwara S, Van Kuijk C. Universal standardization for dual X-ray absorptiometry: patient and phantom cross-calibration results. J Bone Miner Res. 1994; 9:150314.
  • 27
    Hanson J. Standardization of femur bone mineral density. J Bone Miner Res. 1997; 12:13167.
  • 28
    den Uyl D, Bultink IEM, Lems WF. Advances in glucocorticoid-induced osteoporosis. Curr Rheumatol Rep. 2011; 13:23340.
  • 29
    Wang X, Sanyal A, Cawthon PM, Palermo L, Jekir M, Christensen J, Ensrud KE, Cummings SR, Orwoll E, Black DM. Osteoporotic Fractures in Men (MrOS) Research Group, Keaveny TM. Prediction of new clinical vertebral fractures in elderly men using finite element analysis of CT scans. J Bone Miner Res. 2012; 27:80816.
  • 30
    McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med. 2005; 165:17628.
  • 31
    Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J, Saag K, Greenspan SL, Seeman E, Boonen S, Meeves S, Lang TF, Bilezikian JP. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab. 2008; 93:378593.
  • 32
    Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. J Clin Invest. 1998; 102:162733.
  • 33
    Sekhon K, Kazakia GJ, Burghardt AJ, Hermannsson B, Majumdar S. Accuracy of volumetric bone mineral density measurement in high-resolution peripheral quantitative computed tomography. Bone. 2009; 45:4739.
  • 34
    Dempster DW. Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res. 1989; 4:13741.
  • 35
    Dalle Carbonare L, Arlot ME, Chavassieux PM, Roux JP, Portero NR, Meunier PJ. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res. 2001; 2001: (16):97103.
  • 36
    Chappard D, Josselin N, Rouge-Maillart C, Legrand E, Basle MF, Audran M. Bone microarchitecture in males with corticosteroid-induced osteoporosis. Osteoporos Int. 2007; 18:48794.
  • 37
    Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, Dalsky GP, Marcus R. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007; 357:202839.
  • 38
    Langdahl BL, Marin F, Shane E, Dobnig H, Zanchetta JR, Maricic M, Krohn K, See K. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int. 2009; 20:2095104.
  • 39
    Burshell AL, Möricke R, Correa-Rotter R, Chen P, Warner MR, Dalsky GP, Taylor KA, Krege JH. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Bone. 2010; 46:9359.
  • 40
    Arlot M, Meunier PJ, Boivin G, Haddock L, Tamayo J, Correa-Rotter R, Jasqui S, Donley DW, Dalsky GP, Martin JS, Eriksen EF. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res. 2005; 20:124453.
  • 41
    Wolfram U, Wilke HJ, Zysset PK. Rehydration of vertebral trabecular bone: influences on its anisotropy, its stiffness and the indentation work with a view to age, gender and vertebral level. Bone. 2010; 46:34854.
  • 42
    van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int. 2006; 79:12937.
  • 43
    van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000; 15:9931000.
  • 44
    Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, Boonen S, Audran M, Barker C, Anastasilakis AD, Fraser WD, Nickelsen T. for the EUROFORS Investigators. Effects of two years of daily teriparatide treatment on bone mineral density in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res. 2008; 23:1591600.
  • 45
    Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009; 60:334655.